Where does Dianthus Therapeutics's cash flow data come from?

Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q3 '25	Q2 '25	Q1 '25	Q4 '24
Net income	-$40.83M-11.1%	-$36.77M-16.2%	-$31.63M-7.2%	-$29.51M-3.8%	-$28.44M-13.0%
Depreciation and amortization	$32K+18.5%	$27K-10.0%	$30K+11.1%	$27K+3.8%	$26K+4.0%
Stock-based compensation	$10.6M+83.0%	$5.79M+1.5%	$5.71M+7.4%	$5.32M+35.7%	$3.92M+2.0%
Change in accounts receivable	$1.18M-76.3%	$4.96M—	——	$1M—	——
Change in other assets	$2.33M+6,560%	$35K—	——	$1.91M+63.1%	$1.17M+210%
Change in deferred revenue	$849K-82.2%	$4.76M+7,309%	-$66K-15.8%	-$57K-102%	$2.39M—
Non-cash operating lease expense	$44K-38.9%	$72K+4.3%	$69K-34.9%	$106K+104%	$52K-42.9%
Net cash from operating activities	-$28.86M+5.6%	-$30.56M-27.9%	-$23.89M+13.5%	-$27.63M-0.7%	-$27.44M-29.0%
Capital expenditures	$10K+100%	$5K-89.1%	$46K+91.7%	$24K-22.6%	$31K+24.0%
Purchases of investments	$238.59M-14.7%	$279.84M+745%	$33.11M-50.8%	$67.32M-37.7%	$108.08M-61.2%
Proceeds from maturities/sales of investments	$104.63M+33.2%	$78.57M+31.8%	$59.6M-27.4%	$82.14M-3.4%	$85M+347%
Net cash from investing activities	-$133.97M+33.4%	-$201.28M-861%	$26.45M+78.8%	$14.79M+164%	-$23.11M+91.1%
Proceeds from issuance of common stock	$120K-35.8%	$187K—	——	$129K-99.7%	$39.2M—
Net cash from financing activities	$739.41M+169%	$274.51M+48,230%	$568K+253%	$161K-99.6%	$39.68M+13,304%
Net increase (decrease) in cash	$576.58M+1,251%	$42.68M—	——	-$12.68M-16.5%	-$10.88M+96.1%
Accounts Payable Accrued Expenses And Operating Lease Liabilities	$7M+133%	$3M-2.8%	$3.09M+306%	-$1.5M-166%	$2.28M-59.7%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.22M-47.3%	$2.31M+110%	$1.1M-42.2%	$1.9M-30.6%	$2.74M+16.9%
Depreciation	$32K+18.5%	$27K-10.0%	$30K+11.1%	$27K+3.8%	$26K+4.0%
Gain Loss On Investment In Former Related Parties	-$302K—	——	——	$5K—	——
Deferred revenue	$849K-82.2%	$4.76M+7,309%	-$66K-15.8%	-$57K-102%	$2.39M—
Increase (Decrease) in Other Operating Assets	$2.12M+2,485%	-$89K—	——	-$2M-140%	$5.05M+211%
Increase (Decrease) in Prepaid Expense and Other Assets	$2.33M+6,560%	$35K—	——	$1.91M+63.1%	$1.17M+210%
Increase Decrease In Receivable From Former Related Party	$0—	——	——	-$807K—	——
Operating lease right-of-use asset amortization	$44K-38.9%	$72K+4.3%	$69K-34.9%	$106K+104%	$52K-42.9%
Payments for Capital Improvements	$10K+100%	$5K-89.1%	$46K+91.7%	$24K-22.6%	$31K+24.0%
Proceeds From Sale And Maturity Of Available For Sale Securities	$104.63M+33.2%	$78.57M+31.8%	$59.6M-27.4%	$82.14M-3.4%	$85M+347%
Payments Of Issuance Costs Public Offering	$1.34M—	——	——	$0—	——
Proceeds From Issuance Of Common Stock Public Offering	$677.62M—	——	——	$0—	——
Proceeds From Warrant Exercises	$1K—	——	——	$1K—	——
Issuance Costs In Connection With Public Offering Included In Accounts Payable	$50K—	——	——	$0—	——
Issuance Costs In Connection With Public Offering Included In Accrued Expenses	$151K—	——	——	$0—	——
Receivable Associated With Exercise Of Stock Options	$6.45M—	——	——	$0—	——
Free cash flow	-$28.87M+5.5%	-$30.56M-27.7%	-$23.94M+13.4%	-$27.65M-0.7%	-$27.48M-29.0%
Free cash flow	-$28.87M+5.5%	-$30.56M-27.7%	-$23.94M+13.4%	-$27.65M-0.7%	-$27.48M-29.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dianthus Therapeutics's cash flow data come from?: Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.